---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007848"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:56:47.251921+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q1 net loss $62M ($0.57/shr); cash $898M; RLY-2608 combo arm initiated

## Summary
- Net loss of $62.0M ($0.57/shr) vs $42.2M ($0.47) in Q1 2021; R&D expenses rose to $51.7M.
- Cash, equivalents and investments $898M (down from $958M at Dec 31, 2021); sufficient into 2025.
- Initiated fulvestrant combination arm of RLY-2608 (pan-mutant PI3Kα inhibitor) dose escalation; initial data expected H1 2023.
- RLY-4008 (FGFR2 inhibitor) received FDA orphan drug designation for cholangiocarcinoma; expansion cohorts enrolling.
- Virtual analyst/investor event on June 27, 2022 to announce new target.

## SEC filing metadata
- accession: 0000950170-22-007848
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022007848/0000950170-22-007848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022007848/rlay-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007848
- JSON: https://secwatch.observer/filing/0000950170-22-007848.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.